Barely Significant
← all excerpts

Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses.

J Prev Alzheimers Dis · 2026 · PMC13234467 · PMID 42202469

Europe PMCDOI
1
hedged sentence
0.0520
closest p · 1.0× alpha
0.0520
boldest claim

The sentences

did not reach statistical significancep=0.052so close (0.05 < p ≤ 0.1)
Although the treatment effect for community affairs showed a favourable trend for donanemab (16.2% slowing), the difference did not reach statistical significance (p=0.052) ( Fig. 1 F). 3.1.2.1.2.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.